Serum and CSF soluble CD26 and CD30 concentrations in healthy pediatric surgical outpatients

Tissue Antigens

Volumn 80, Issue 4, 2012, Pages 368-375

  Delezuch, W ^a,b   Marttinen, P ^c   Kokki, H ^a,b   Heikkinen, M ^b   Vanamo, K ^b   Pulkki, K ^a   Matinlauri, I ^d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c AALTO UNIVERSITY   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Bayesian approach; Reference intervals; Regression model; SCD26; SCD30

Indexed keywords

CD30 ANTIGEN; DIPEPTIDYL PEPTIDASE IV;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PEDIATRIC SURGERY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; REFERENCE VALUE; SCHOOL CHILD; SEX DIFFERENCE; SURGICAL PATIENT;

ADOLESCENT; ANTIGENS, CD30; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIPEPTIDYL PEPTIDASE 4; FEMALE; HUMANS; INFANT; LYMPHOCYTE ACTIVATION; MALE; OUTPATIENTS; REFERENCE VALUES; SEX FACTORS; SOLUBILITY; SURGICAL PROCEDURES, ELECTIVE; TH1 CELLS; TH2 CELLS;

EID: 84866605550     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2012.01938.x     Document Type: Article

References (36)

1. Kemp K, Kurtzhals JAL, Akanmori BD et al. Increased levels of soluble CD30 in plasma of patients with Plasmodium falciparum malaria. Clin Diagn Lab Immunol 2002: 9: 720-2.
2. Liao YR, Po-Yen C, Lin CC, Fu LS, Chiu CC, Chi CS. Soluble CD26/30 levels before and after treatment with interferon-alpha and ribavirin combination therapy in a pediatric hepatitis C patient. J Microbiol Immunol Infect 2004: 37: 67-70.
3. Jafari-Shakib R, Shokrgozar MA, Nassiri-Kashani M, Malakafzali B, Nikbin B, Khamesipour A. Plasma sCD26 and sCD30 levels in cutaneous leishmaniasis. Acta Trop 2009: 109: 61-3.
4. Heshmat NM, El-Haddidi ES. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. Pediatr Allergy Immunol 2006: 17: 297-303.
5. Lun SWM, Wong CK, Ko FWS, Hui DSC, Lam CWK. Increased expression of plasma and CD4+ T lymphocyte costimulatory molecule CD26 in adult patients with allergic asthma. J Clin Immunol 2007: 27: 430-7.
6. Gerli R, Lunardi C, Bocci EB et al. Anti-tumor necrosis factor-α response in rheumatoid arthritis is associated with an increase in serum soluble CD30. J Rheumatol 2008: 35: 14-9.
7. Savolainen E, Matinlauri I, Kautiainen H, Luosujärvi R, Kaipiainen-Seppänen O. Serum soluble CD30 in early arthritis: a sign of inflammation but not a predictor of outcome. Clin Exp Rheumatol 2008: 26: 922-5.
8. Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM. Elevations in IFN-γ, IL-5, and IL-10 in patients with autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol 1996: 80: 311-20.
9. Pellegrini P, Totaro R, Contasta I, Berghella AM, Carolei A, Adorno D. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. Neuroimmunomodulation 2005: 12: 220-34.
10. Pelzl S, Opelz G, Wiesel M et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002: 73: 3-6.
11. Matinlauri IH, Kyllönen LEJ, Salmela KT, Helin H, Pelzl S, Süsal C. Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations. Transplantation 2005: 80: 1809-12.
12. Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med 2000: 343: 108-17.
13. Del Prete G, De Carli M, Almerigogna F et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995: 9: 81-6.
14. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995: 85: 1-14.
15. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995: 57: 726-30.
16. Pellegrini P, Berghella AM, Contasta I, Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between Th1/Th2 response. Transpl Immunol 2003: 12: 49-61.
17. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998: 161: 55-70.
18. Dong RP, Tachibana K, Hegen M et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997: 159: 6070-6.
19. Hegen M, Niedobitek G, Klein CE, Stein H, Fleischer B. The T cell triggering molecule Tp103is associated with dipeptidyl aminopeptidase IV activity. J Immunol 1990: 144: 2908-14.
20. Masuyama J, Berman JS, Cruikshank WW, Morimoto C, Center DM. Evidence for recent as well as long-term activation of T cells migrating through endothelial cell monolayers in vitro. J Immunol 1992: 148: 1367-74.
21. Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline - third edition CLSI document C28-A3; 2008.
22. Virtanen A, Kairisto V, Irjala K, Rajamäki A, Uusipaikka E. Regression-based reference limits and their reliability: example on hemoglobin during the first year of life. Clin Chem 1998: 44: 327-35.
23. Virtanen A, Uusipaikka E. Computation of profile likelihood-based confidence intervals for reference limits with covariates. Stat Med 2008: 27: 1121-32.
24. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis, 2nd edn. Boca Raton, Florida: Chapman & Hall/CRC Press, 2003.
25. Bernardo JM, Smith AFM. Bayesian Theory. Chichester: John Wiley & Sons Ltd, 1994.
26. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comp 2000: 10: 325-37.
27. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. J Roy Stat Soc Ser B Stat Met 2002: 64: 583-639.
28. Shames RS. Gender differences in the development and function of the immune system. J Adolesc Health 2002: 30S: 59-70.
29. Calder AE, Hince MN, Dudakov JA, Chidgey AP, Boyd RL. Thymic involution: Where endocrinology meets immunology. Neuroimmunomodulation 2011: 18: 281-9.
30. Remes ST, Delezuch W, Pulkki K, Pekkanan J, Korppi M, Matinlauri IH. Association of serum - soluble CD26 and CD30 levels with asthma, lung function and bronchial hyper-responsiveness at school age. Acta Pediatrica 2011: 100: e106-11.
31. Tulic MK, Andrews D, Crook ML et al. Changes in thymic regulatory T-cell maturation from birth to puberty: differences in atopic children. J Allergy Clin Immunol 2012: 129: 199-206.
32. Hanekom WA, Hussey GD, Hughes EJ, Potgieter S, Yogev R, Check IJ. Plasma-soluble CD30 in childhood tuberculosis: Effects of disease severity, nutritional status and vitamin A therapy. Clin Diagn Lab Immunol 1999: 6: 204-8.
33. Chen JY, Fu LS, Chu JJ, Chen HC, Chi CS. Plasma soluble CD30 level correlates negatively with age in children. J Microbiol Immunol Infect 2007: 40: 168-72.
34. Chrul S, Polakowska E. Age-dependent changes of serum soluble CD30 concentration in children. Pediatr Transplant 2011: 15: 515-8.
35. Krampera M, Vinante F, Tavecchia L et al. Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration. Clin Exp Immunol 1999: 117: 291-7.
36. Hibbert DB, Armstrong N. An introduction for analyzing chemistry data Part II: a review of applications of Bayesian methods in chemistry. Chemometr Intell Lab Syst 2009: 97: 211-20.